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SNF5/INI1 is a component of the ATP-dependent chromatin remodeling enzyme family SWI/SNF. Germ line
mutations of INI1 have been identified in children with brain and renal rhabdoid tumors, indicating that INI1
is a tumor suppressor. Here we report that disruption of Ini1 expression in mice results in early embryonic
lethality. Ini1-null embryos die between 3.5 and 5.5 days postcoitum, and Ini1-null blastocysts fail to hatch,
form the trophectoderm, or expand the inner cell mass when cultured in vitro. Furthermore, we report that
approximately 15% of Ini1-heterozygous mice present with tumors, mostly undifferentiated or poorly differ-
entiated sarcomas. Tumor formation is associated with a loss of heterozygocity at the Ini1 locus, characterizing
Ini1 as a tumor suppressor in mice. Thus, Ini1 is essential for embryo viability and for repression of onco-
genesis in the adult organism.
The compact nature of chromatin structure presents a bar-
rier to cellular processes that require access to DNA. A num-
ber of multiprotein complexes have been identified that share
the ability to modify chromatin structure. These include the
histone acetyltransferases and deacetylases, complexes which
chemically modify the amino-terminal tails of histones by the
addition or removal of acetyl groups, respectively, as well as a
group of enzymes that utilize the energy derived from ATP
hydrolysis to alter nucleosome structure (16, 20, 43, 44, 50).
Included among these ATP-dependent chromatin remodeling
enzymes is the SWI/SNF family of chromatin modifiers.
SWI/SNF enzymes are large multisubunit enzymes of ;1 to
2 MDa. Yeast SWI/SNF genes were originally identified as
being required for mating type switching or sucrose fermenta-
tion (4, 32, 42). Later work determined that SWI/SNF genes
were required for the induction of a subset of yeast genes and
that the SWI2/SNF2 protein possessed a DNA-stimulated
ATPase activity (6, 22, 26, 33, 34, 54). Mutations in SWI/SNF
genes could be suppressed by mutations altering histone gene
expression, histone structure, or nonhistone chromatin pro-
teins, leading to the suggestion that these gene products facil-
itated transcriptional activation by altering chromatin structure
(15, 23, 24).
Human SWI/SNF (hSWI/SNF) complexes contain either the
human BRM (hBRM) (hSNF2a) or BRG1 (hSNF2b) homo-
logues of the yeast SWI2/SNF2 ATPase (7, 19, 30). Both yeast
and human SWI/SNF complexes have been shown to possess
nucleosome remodeling activity in vitro (8, 17, 25). Compo-
nents of mammalian SWI/SNF complexes have been impli-
cated in a variety of cellular processes, including gene activa-
tion and repression, development and differentiation,
recombination and repair, and cell cycle control. There is ev-
idence supporting a role for SWI/SNF in gene activation events
mediated by nuclear hormone receptors, environmental stress,
and viral infection (1, 7, 10, 13, 30). In contrast, SWI/SNF
components also were shown to be involved in repression of
c-fos and some E2F-regulated genes (31, 48). Both BRG1 and
hBRM can interact with the retinoblastoma oncoprotein and
induce cell cycle arrest, an effect that is abrogated by the
association of BRG1 with cyclin E (11, 41, 45, 56). Evidence
suggesting a role for hSWI/SNF in recombination and repair
was provided by studies demonstrating an interaction of com-
ponents of the hSWI/SNF complex with BRCA1, which is
thought to be involved in DNA damage and repair pathways
(3). Furthermore, members of the SWI/SNF complex are tar-
gets of viral regulatory proteins upon infection of cells by
adenovirus, Epstein-Barr virus, human immunodeficiency vi-
rus, and human papillomavirus (18, 27, 28, 53).
The role of SWI/SNF enzymes in whole organisms is un-
clear. While homozygous disruption of Brg1 in mouse embry-
onic carcinoma cells resulted in lethality, disruption of Brm
expression in mice produced only mild proliferative effects (35,
46). The upregulation of Brg1 in the Brm-deficient mice may
provide a compensatory effect; however, one cannot rule out
the possibility that these differences are due to distinct func-
tions of Brm- or Brg1-containing complexes.
SNF5/INI1 is a member of both BRG1- and BRM-contain-
ing SWI/SNF complexes (29, 51). INI1 was shown to interact
with ALL-1, translocations of which are associated with several
types of human acute leukemias (37). Furthermore, INI1 has
been found to be altered in malignant rhabdoid tumors, cho-
roid plexus carcinomas, medullablastomas, and central primi-
tive neuroectodermal tumors (2, 9, 39, 40, 49). Identification of
constitutional mutations in a subset of these tumors indicates
that INI1 is a tumor suppressor (2, 40). In an attempt to
generate a mouse model that would allow further character-
ization of the mechanisms of Ini1 in tumorigenesis and to
determine the role of the mammalian SWI/SNF complexes in
development, we generated mice deficient for Ini1 expression.
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We show that Ini1-deficient mice die early in embryogenesis,
likely due to an inability of the blastocysts to hatch, implant in
the uterus, and continue development. In addition, we report
that a subset of the Ini1-heterozygous mice present with a
variety of tumors in the soft tissues of the head and neck and
that loss of heterozygosity at the Ini1 locus is correlated with
tumor formation.
MATERIALS AND METHODS
Ini1 targeting. Embryonic stem (ES) cells (Omnibank no. OST32815) bearing
a retroviral promoter trap that functionally inactivates one allele of Ini1 were gen-
erated as described previously (55). Analysis by rapid amplification of cDNA ends
also is described. The site of insertion was determined using sequence analysis.
Creation of Ini1-null mice. Ini1-targeted ES cells were injected into 3.5 days
postcoitum (d.p.c.) C57BL/6 blastocysts. Male chimeric mice were mated with
wild-type C57BL/6 or 129 females. Germ line transmission of the mutant allele
was determined by PCR analysis of tail genomic DNA using the following
primers: for Ini1, 59-GCAAGCGCTCTGCCAATTGACC-39 and 39-CACACC
CTATTGTCACTCTGGAA-59; bgeo, 59-CGGTATCGATAAGCTTGATGA
TC-39 and 39-GTCAACGCGTCGGACTTACCGC-59. Ini1-heterozygous mice
were intercrossed to generate Ini1-null mice. Embryos 6.5 d.p.c. and younger
were prepared for genotyping by PCR as described previously (47). Nested PCR
was done using the above primers for the first round of PCR (29 cycles) and the
following intron 3-nested primers for the second round (29 cycles): 59-GCGTG
CGCCACCATGCCTGG-39 and 39-CTTCTGGAGACTTCACTTACGTCC-59.
Blastocyst culture. Blastocysts from heterozygous intercrosses were flushed
from the uteri of Ini1in3/1 females 3.5 d.p.c. with M15 media (Dulbecco’s min-
imal essential medium, 15% fetal calf serum, 100 mM b-mercaptoethanol, 2 mM
glutamine, and 13 penicillin-streptomycin) and cultured in tissue culture plates
for 96 h. Embryo cultures were genotyped as described above.
b-Galactosidase staining of cultured ES cells. Wild-type AB2.2 ES cells and
Ini1in3/1 ES cells were grown to near-confluency and fixed in 0.5% glutaralde-
hyde. Cells were then rinsed with phosphate-buffered saline and stained over-
night in the dark at room temperature in a solution containing 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl2, and 1 mg of 5-bromo-
4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal)/ml.
Whole mount staining of embryos for b-galactosidase activity. Embryos were
harvested at various time points postfertilization and fixed in 4% paraformalde-
hyde for 20 min at 4°C. Embryos were washed and then stained in an X-Gal his-
tochemical reaction mixture (4 mM potassium ferrocyanide, 4 mM potassium ferri-
cyanide, 2 mM MgCl2, 1 mg of X-Gal/ml) overnight at room temperature. Following
staining, embryos were rinsed in phosphate-buffered saline and cleared in 30% sucrose.
Western analysis of tumor samples. Control tissues and tumor samples were
homogenized in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl,
0.5% NP-40, 20% glycerol, 1 mM dithiothreitol, 1 mg of pepstatin A/ml, 4 mg of
leupeptin/ml, and 1 mM phenylmethylsulfonyl fluoride. Extracts were resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western analysis
for Ini1 protein was performed as described previously (10).
Histologic analysis of tumors in mice. Tumor samples and selected tissues
were fixed in 10% buffered formalin phosphate and processed for paraffin em-
bedding as described previously (14). Sections were prepared, stained with he-
matoxylin and eosin, and examined under a microscope.
RESULTS AND DISCUSSION
Mouse ES cells bearing a retroviral promoter trap that func-
tionally inactivates one allele of Ini1 were constructed as de-
scribed previously (55). Sequence analysis revealed that the
promoter trap was inserted within intron 3 of Ini1 (Fig. 1A).
The beta-galactosidase-neomycin (b-geo) gene fusion cassette
within the retroviral insertion has a 59 splice acceptor site; thus,
b-geo expression is regulated by the native Ini1 promoter. We
were able to utilize the b-geo gene cassette in a colorimetric
assay to determine if Ini1 is normally expressed in ES cells.
Ini1-targeted cells stained positive for b-galactosidase activity,
indicating that Ini1 is expressed in ES cells (Fig. 2A). Northern
analysis of ES cell total RNA confirmed Ini1 expression (data
FIG. 1. Disruption of Ini1. (A) Targeting strategy for Ini1. A retroviral promoter trap vector was inserted in intron 3 of Ini1. sa and sd, the splice
acceptor site in the b-geo gene cassette and the splice donator site in the puromycin selection marker, respectively. Carets represent the site of
alternate splicing. Positions of the primers used for PCR analysis are shown. LTR (del), long terminal repeat deleted; An, polyadenylation signal;
Puro, puromycin. (B) Genotyping of Ini1-targeted mice by PCR. Genomic DNA was harvested from tails and genotyped as described in Materials
and Methods. The size and position of wild-type (WT) and targeted bands are indicated. (C) Genotyping of Ini1-targeted embryos. Embryos
6.5 d.p.c. and younger were genotyped by nested PCR. The size and position of wild-type and targeted bands are indicated.
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not shown). Furthermore, sequence data obtained from 59
rapid amplification of cDNA ends analysis of the Ini1–b-ga-
lactosidase fusion mRNA revealed that transcripts utilizing
either splice donor site in exon 2 spliced into the trap, indicat-
ing that both splice variants of Ini1 were inactivated (5).
To determine the role of Ini1 in mammalian development
and tumorigenesis, we used the targeted ES cells in blastocyst
injection experiments to generate Ini1-heterozygous (Ini1in3/1)
mice. In order to monitor expression of Ini1 during embryo-
genesis, we performed whole mount staining for b-galactosi-
dase activity in embryos harvested from Ini1in3/1 matings at
various times during development. We found that Ini1in3/1
embryos stained positive in all tissues at all time points exam-
ined, including 6.5, 8.5, 9.5, and 10.5 d.p.c., indicating that Ini1
is ubiquitously expressed during embryogenesis (Fig. 2B). Ini1
expression was also detected by Northern analysis in a wide
range of adult tissues (35) (data not shown).
Chimeric mice generated from C57BL/6 strain blastocyst
injections of the 129 strain-derived ES cells were bred to wild-
type C57BL/6 or 129 mice in order to obtain Ini1in3/1 mice on
either a mixed (C57BL/6 3 129) or pure (129) background.
Intercrosses of Ini1in3/1 mice in both backgrounds yielded
Ini1in3/1 offspring and wild-type offspring at a 2:1 ratio (63:26
in the mixed background, 34:17 in the pure background) and
no Ini1-null offspring, indicating that disruption of Ini1 induces
embryonic lethality (Fig. 1B). Timed matings of Ini1in3/1 mice
were performed, and embryos were harvested at various time
points in gestation for genotyping via PCR. Ini1-null embryos
could be isolated at 3.5 d.p.c. and were normal in appearance
(Fig. 1C and 3). However, no Ini1in3/in3 embryos were detected
at 6.5 d.p.c. or later (Table 1). Dissection of maternal deciduae
at 6.0 to 6.5 d.p.c. revealed no significant increase in the num-
ber of embryo reabsorptions, suggesting that Ini1in3/in3 lethality
occurred between days 3.5 and 5.5 of gestation. These results
FIG. 2. Ini1 is expressed in ES cells and ubiquitously throughout
development. (A) b-galactosidase staining of targeted ES cells showing
expression of Ini1. Wild-type (WT) AB2.2 ES cells were used as a
control. (B) Whole mount staining of Ini1in3/1 embryos showing ubiq-
uitous expression of Ini1 at indicated time points. Wild-type embryos
at 6.5 and 10.5 d.p.c. are shown as controls.
FIG. 3. Ini1-null mice are early embryonic lethal and fail to hatch
in vitro. Blastocysts were harvested from C57BL/6 Ini1in3/1 females
and plated in culture for 96 h, at which time outgrowths were pro-
cessed for PCR. Blastocysts are shown before and after culturing. TE,
trophectoderm; ICM, inner cell mass.
TABLE 1. Genotyping of embryos from heterozygous intercrossesa
Embryo category
No. of embryos
WT Het Null
3.5 d.p.c. 7 17 5
In vitro culture 11 14 1b
6.5 d.p.c. 9 23 0
8.5 d.p.c. 4 14 0
13.5 d.p.c. 5 6 0
a WT, wild type; Het, heterozygous.
b The embryo was dead.
TABLE 2. Tumor occurrence
Mouse
no.
Age
(wk) Tumor site Classification
Ini 119 36 Face Undifferentiated sarcoma
Ini 44 32 Face Undifferentiated sarcoma
Ini 138 23 Face Malignant fibrous histiocytoma
Ini 100 23 Face Malignant fibrous histiocytoma
Ini 180 31 Face Undifferentiated sarcoma
Ini 26a 24 Face Malignant fibrous histiocytoma
Ini 262 16 Face Malignant fibrous histiocytoma
Ini 29a 41 Face Malignant fibrous histiocytoma
Ini 13a 59 Face/eye Liposarcoma
Ini 56 52 Neck mass Lymphoma
Ini 322 21 Brain Undifferentiated sarcoma
Ini 10 32 Ventral to brain Undifferentiated sarcoma
Ini 95a 22 Face mass Malignant fibrous histiocytoma
Ini 127 12 Neck mass Lymphoproliferative disorder
Ini 328 25 Eye Undifferentiated sarcoma
a 129 strain.
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FIG. 4. Ini1-heterozygous mice present with various tumors. Microscopic features of different tumors from Ini1in3/1 mice. Parafin-embedded
tumors were sectioned, stained with hematoxylin and eosin, and examined under a microscope at magnification 375. Mouse numbers corre-
sponding to those presented in Table 2 are indicated in each panel.
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indicate that Ini1-null embryos either failed to be implanted
into the uterine wall or were implanted and were reabsorbed
shortly thereafter. In order to examine further the develop-
mental defect of Ini1in3/in3 embryos, we analyzed the ability of
blastocysts from Ini1in3/1 intercrosses to expand in vitro. When
3.5-d.p.c. blastocysts were plated in culture, wild-type and
Ini1in3/1 blastocysts hatched from the zona pellucida and were
implanted onto the tissue culture plastic. Both wild-type and
Ini1in3/1-implanted embryos formed the trophectoderm and
expanded their inner cell mass (ICM). In contrast, no Ini1in3/in3
blastocysts hatched and were implanted in culture (Fig. 3). The
results of these experiments suggest that the peri-implantation
embryonic lethality of Ini1-null mice may be due to a defect in
the hatching of the blastocyst from the zona pellucida, an ob-
ligate step for implantation of the embryo into the wall of the
uterus during normal development. Manual disruption of the
zona pellucida of 19 (C57BL/6 3 129) blastocysts harvested
from Ini1in3/1 intercrosses did not result in expansion of the Ini1-
null trophectoderm or ICM during in vitro culture, suggest-
ing that growth of these tissues also is compromised (data not
shown). Expression of Ini1 in ES cells, which are derived from the
ICM of 3.5 d.p.c. blastocysts, is consistent with a gene crucial to
the peri-implantation or preimplantation stage of embryogenesis.
In humans, loss of INI1 is correlated with a variety of tu-
mors, the vast majority of which are neuronal or renal in na-
ture. To date, most human malignant rhabdoid tumors and
choroid plexus carcinomas examined have deletions and/or
mutations in INI1, as do a subset of central primitive neuro-
ectodermal tumors and medullablastomas (39). In mice, we
found that approximately 15% of Ini1 heterozygotes in both
the mixed F1 (C57BL/6 3 129) or pure 129 backgrounds pre-
sented with tumors. All of these tumors arose in the head or
neck regions of the mice, particularly in the soft tissue of the
face (Table 2). While 2 of the 15 mouse tumors analyzed thus
far had varying degrees of rhabdoid-like cells, none had the
characteristic, monomorphous appearance of human rhabdoid
tumors. Two Ini1in3/1 mice were found to have a lymphopro-
liferative disorder or lymphoma originating in an ill-defined
region on the neck (Fig. 4). Two-thirds of the tumors origi-
nated on the faces of the mice. Interestingly, expression of Ini1
appears to be elevated during development in the branchial
arch and in the frontonasal and maxillary processes (Fig. 2B),
structures which contribute to formation of the face. While the
majority of the facial tumors were poorly differentiated or
undifferentiated sarcomas and not neuronal in origin, it is
possible that the tumors arose in cells derived from neural
crest progenitors, since neural crest cells, along with mesoder-
mal cells, coordinate to form the facial primordia (12, 38).
We have analyzed tumors in three representative mice. North-
ern analysis of total RNA harvested from tumor tissue indi-
cated the presence of wild-type-length Ini1 message (data not
shown). However, Western blot analysis of proteins harvested
from these tumors revealed the absence of Ini1 protein in all
three samples (Fig. 5). This indicates that loss of heterozygos-
ity at the Ini1 locus is responsible for tumor formation in the
Ini1in3/1 mice.
The mechanism of Ini1-mediated tumor suppression is un-
clear. Other subunits of the human and mouse SWI/SNF chro-
matin remodeling complexes have been reported to associate
with known tumor suppressors, including Rb and Brca1 (3, 11,
48, 56), and several of the SWI/SNF subunits appear to be
molecular targets of viral regulators of cell proliferation (18,
27, 28, 53). In addition, one of these subunits, BRG1, recently
has been reported to be missing or mutated in a variety of
human tumor cell lines, and reintroduction of BRG1 into these
tumor cells reverses their transformed morphology (52). These
findings suggest a role for chromatin remodeling in regulation
of cell growth and/or in tumor suppression.
While this report was in preparation, Roberts et al. and
Klochendler-Yeivin et al. published data consistent with our
findings (21, 36). The fact that these results are reproducible in
knockout lines generated by different targeting strategies con-
firms the importance of Ini1 in development and tumorigene-
sis. Klochendler-Yeivin et al. (21) further report in their study
that Ini1-deficient embryos can induce the formation of ma-
ternal decidua, suggesting that Ini1-deficient embryos undergo
hatching and implantation prior to their demise. In contrast,
Ini1in3/in3 embryos fail to hatch from the zona pellucida, sug-
gesting that subtle strain variations may influence the precise
timing of embryonic lethality. In agreement with these other
groups, a percentage of the Ini1-heterozygous mice in our
colony presented with tumors that contained variable numbers
of rhabdoid cells. However, we are hesitant to classify these
undifferentiated sarcomas as true rhabdoid tumors, which are
described as monomorphous tumors in the human population.
Discrepancies between tumor types associated with disruption
of Ini1 in humans and in mice may be due to differences in
species-specific differentiation pathways. Regardless, the Ini1-
heterozygous mice should provide a useful model for studying
the general mechanisms involved in tumor suppression by Ini1.
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